|Rosetta Genomics Ltd -- USA Stock|| |
USD 0.9199 0.0199 2.21%
Mr. Oded Biran serves as General Counsel of the company, since November, 2011. Mr. Biran was an independent attorney between the years 20102011, after previously working for us as legal counsel between June and November 2010. Prior to that, Mr. Biran was an associate in the law offices of Sharon Raviv and Co., a boutique law firm specializing in technology and communications, between December 2009 and June 2010. During the years of 2008 and 2009, Mr. Biran was an associate in Raved Magriso, Benkel, Lahav and Co.s, where he practiced in the corporate and securities department, specializing in corporate, technology, IP and complex mergers and acquisitions transactions. During 20062007, Mr. Biran was an associate at Gabriel Reubinoff and Co.s Tel Aviv office where he coheaded the firms class action department
Age: 35 Executive Since 2011
972 73 222 0700 http://www.rosettagenomics.com
Biran holds a L.L.B degree from the Hebrew University in Jerusalem and is a member of the Israeli Bar Association.
The company has return on total asset (ROA)
of (60.19) %
which means that it has lost $60.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (137.95) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics Ltd has Current Ratio of 2.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Rosetta Genomics Ltd. develops and commercializes microRNAbased and other molecular diagnostics. Rosetta Genomics Ltd (ROSG) is traded on Nasdaq Capital Markets in USA. It is located in ISRAEL and employs 77 people. Rosetta Genomics is listed under Pharmaceutical Products category by Fama And French industry classification.